Skip to main
OPK

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 50%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health is facing some concerns regarding their Q4 performance, as although they beat expectations, the means in which they achieved it may not be sustainable. Their Diagnostics segment margin was also disappointing, but they did receive strong results from NGENLA gross profit share payments, BARDA revenue, and royalty revenue. Despite these concerns, the company maintains a strong cash position with $369 million in cash and $344 million in debt, giving them flexibility for future growth and development.

Bears say

OPKO Health is facing challenges in their diagnostics segment, with the recent divestiture of oncology assets resulting in a $18.3 million operating loss in the first full quarter since the divestiture. Although they have seen growth in certain tests, the overall performance equates to an annualized adjusted EBITDA loss of over $33.5 million and a $50 million loss in terms of adjusted operating income, leading to doubts on their ability to achieve profitable growth in this segment by 2026. Additionally, the company's recent financial results have been below expectations and we see little reason for the stock to perform well in the near-term.

OPKO Health (OPK) has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 50% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Hold based on their latest research and market trends.

According to 2 analysts, OPKO Health (OPK) has a Hold consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.